Healthcare Services company Suraksha Diagnostic announced Q1FY26 results For Q1FY26, the company reported revenue from operations of Rs 725.86 million, reflecting a growth of 19.52% compared to Q1FY25. EBITDA for Q1FY26 reached Rs 246.56 million, marking a 13.51% increase from Q1FY25. EBITDA margin for Q1FY26 stood at 33.97%. PAT for Q1FY26 stood at Rs 91.75 million, reflecting a growth of 19.67% YoY. PAT margin for Q1FY26 was 12.64%. Ritu Mittal, Joint Managing Director & CEO said: “We are pleased to report a strong performance for Q1FY26, driven by consistent growth across our operations. In the quarter, we have also marked a major milestone with the launch of Suraksha Genomics, this new vertical, equipped with state-of-the-art high-throughput sequencing platforms, positions us at the forefront of precision medicine in Eastern India. Our strategic focus remains ambitious and future-ready. We are actively expanding into whole-genome and metagenomic testing, while integrating AI-assisted variant interpretation to elevate diagnostic accuracy. Additionally, we are laying the groundwork for population-scale genomic screening programs, an initiative that holds transformative potential for public health. Clinical partnerships continue to be a cornerstone of our approach, enabling us to translate scientific advancements into meaningful improvements in patient care and research outcomes. As newer centres stabilise and begin contributing significantly, we expect to see a stronger and more profitable financial profile across our network. We remain committed to innovation, operational excellence, and sustainable growth as we advance our mission to redefine healthcare delivery through genomics.” Result PDF